<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.29123.006</object-id><label>Table 1.</label><caption><title>Kinase profiling results for NCT-504 and ML168.</title><p>Percent activity remaining at 10 &#956;M exposure of NCT-504 and ML168 in KINOMEscan kinase panel/profiling <ext-link ext-link-type="uri" xlink:href="http://www.discoverx.com/technologies-platforms/competitive-binding-technology/kinomescan-technology-platform">http://www.discoverx.com/technologies-platforms/competitive-binding-technology/kinomescan-technology-platform</ext-link>. Top 3 NCT-504 inhibited kinases are reported as single replicate data. Full data set is provided in <xref ref-type="table" rid="table1">Table 1</xref> &#8211; source data file. PIP4K2&#947; potencies were confirmed in triplicate concentration-response testing (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Kinase</th><th valign="top">ML168</th><th valign="top">NCT-504</th></tr></thead><tbody><tr><td valign="top">PIP4K2C</td><td valign="top">23</td><td valign="top">4.9</td></tr><tr><td valign="top">RSK1(Kin.Dom.2-C-terminal)</td><td valign="top">20</td><td valign="top">40</td></tr><tr><td valign="top">GAK</td><td valign="top">10</td><td valign="top">42</td></tr></tbody></table><table-wrap-foot><fn><p>% Control Legend</p><p>0% &#8804; x &lt; 10%</p></fn><fn><p>10% &#8804; x &lt; 35%</p><p>35%&#160;&#8804;&#160;x</p></fn></table-wrap-foot></table-wrap>